- Home
- HKIT vs ARMP Comparison
HKIT vs ARMP Comparison
Compare HKIT & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HKIT | ARMP |
|---|---|---|
| Founded | 1996 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.6M | 125.7M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | HKIT | ARMP |
|---|---|---|
| Price | $1.75 | $6.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 549.5K | 69.4K |
| Earning Date | 04-08-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,812,901.00 | ★ $5,054,000.00 |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.15 | $0.90 |
| 52 Week High | $4.18 | $16.34 |
Technical Indicators
Market Signals| Indicator | HKIT | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 52.54 | 50.12 |
| Support Level | $1.42 | $5.67 |
| Resistance Level | $1.53 | $6.18 |
| Average True Range (ATR) | 0.21 | 0.56 |
| MACD | 0.02 | -0.14 |
| Stochastic Oscillator | 59.37 | 35.56 |
Price Performance
Historical ComparisonAbout HKIT Hitek Global Inc.
Hitek Global Inc is a provider of information technology consulting and solutions services. The company has two lines of businesses such as services to small and medium businesses, which consist of Anti-Counterfeiting Tax Control System tax devices, including Golden Tax Disk and printers, ACTCS services, and IT services; and services to large businesses, which include hardware sales and software sales. It generates revenues from hardware sales, software sales, IT services, and tax devices and services.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.